INTRODUCTION
Endotoxin, the lipopolysaccharide component of Gramnegative bacteria, has been implicated as a causative agent of sepsis, inflammation and organ dysfunction. 1 There is evidence that patients may differ in their response to endotoxin, and that this may partly account for differences in postoperative outcome. [2] [3] [4] [5] [6] Many natural endogenous and potentially therapeutic substances bind to endotoxin in vitro. 7 It may, therefore, be important to develop a human model of endotoxin exposure to study variability in inflammation between individuals in a more controlled manner than the clinical setting. Many previous studies have used the traditional model of 4 ng/kg to gain information on inflammatory mediators, the mechanism of cellular activation and the simultaneous administration of agents that may modify inflammation. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] However, this dosing regimen might not be the best model in which to test endotoxin and inflammatoryrelated therapies. The primary aim of this study was to characterise endotoxin dosing regimens that could elicit variability in systemic inflammation in some subjects but not in others. Our objective was to determine if low-dose regimens of endotoxin cause inter-individual variability in systemic inflammation.
MATERIALS AND METHODS
We used Escherichia coli O:113 endotoxin (EC-6) which was a kind gift from the National Institutes of Health, USA. EC-6 was prepared in conjunction with the Food and Drug Administration under good manufacturing practices for administration to human volunteers. It is supplied as a lyophilized powder, and was reconstituted to the appropriate dilution according to the manufacturer's instructions by the investigational pharmacy.
After Institutional Review Board approval (IRB), we enrolled healthy male and female ambulant adults between the ages of 18 and 55 years from all ethnic groups who, after written informed consent, underwent a screening examination (external physical examination, electrocardiograph) and blood tests (full blood count, electrolytes, liver function tests and urinary pregnancy test). Exclusion criteria included abnormal screening tests, acute or chronic illness, reported illicit drug misuse, recent vaccination or transfusion and pregnancy. Volunteers did not consume any food or liquid after midnight prior to the study. On the morning of the study, two intravenous catheters were inserted into each volunteer, (one for blood sampling, the other in the contralateral arm for the dosing regimen) after which baseline observations and bloods were taken. Using a computer-generated schedule, subjects were randomised to receive one of 6 dosing regimens described in Table 1 . To ensure blinding, a 'double-dummy' procedure was employed whereby each volunteer received a bolus (10 ml over 1 min) and an infusion (50 ml over 30 min) of either water or endotoxin according to which study group they were assigned to (see Table 1 ). Because the effects of 4 ng and 0 ng/kg endotoxin are well known and have been recently described, we decided to randomise most of the volunteers to the 0.25 and 0.75 ng/kg dosing regimens. 20 Over the next 10 h, subjects' vital signs were monitored by an investigator and symptoms (nausea, vomiting, myalgia, headache, shivering) were recorded hourly by the volunteer on a self-reporting visual analogue scale from 0 to 10. For example, volunteers were asked 'on a scale on 0 to 10, (0 being not present at all, 10 being the worst), how nauseated do you feel?'. Blood samples were taken into sterile, additive-free tubes, allowed to clot, spun and the serum aliquoted and frozen at -80°C for later analysis. This was performed halfhourly for the first 2 h, hourly until the 6th hour, then at 8 and 10 h. We measured temperature, white cell count, platelet count, C-reactive protein (CRP), tumour necrosis factor (TNF)-α, interleukin 6 (IL-6) and interleukin 10 (IL-10) changes from baseline. 20 Clinical and laboratory measurements were performed blinded to the subjects' endotoxin dose group.
Baseline screening tests, white cell counts, platelet counts and C-reactive protein levels were performed at the New York Presbyterian Medical Centre (New York, NY, USA) using certified College of American Pathologists' methods. Cytokine assays were performed using Biosource ELISA Cytoset kits (Biosource International CA, USA) according to the manufacturer's instructions by a single investigator, in duplicate, and in as large a batch as possible to reduce assay variability. A standard curve provided by the manufacturer and a quality control serum were included on each ELISA plate. Correlation coefficients were calculated using SPSS (SPSS 11.5, Chicago, IL, USA).
RESULTS
Thirty volunteers were screened, consented, and randomised to one of six dosing regimens (Table 1) . Their characteristics are presented in Table 2 . Maximum increases from baseline (in temperature and white cell count) or fall (in platelet count) are shown in Figure 1 . cell count similar to placebo, whilst others were similar to those subjects receiving the 4 ng/kg dose (Table 4) .
Although not the primary aim of the study, there were weak associations between changes in several of the outcome measures, notably, temperature and TNF-α, IL-6 and CRP and between CRP and TNF-α (presented in Fig. 3 ), although not between CRP and other cytokines (data not shown). The percentage of volunteers in each dosing regimen with a symptom scored at 1 (or more) out of 10 for at least 2 consecutive time-points.
DISCUSSION
We have been able to identify several low-dose endotoxin regimens that elicit variability in the inflammatory response between individuals. There are several factors that strengthen our observations. Our study design included both positive (4 ng/kg) and negative placebo (0 ng/kg) controls. Those receiving the 4 ng/kg regimen had rises in many inflammatory markers comparable to those reported in previous studies, suggesting that: (i) there was no binding of endotoxin to our dosing equipment; (ii) the volunteers were receiving the designed doses; and (iii) the assays were working correctly and were appropriately sensitive. 8, 20, 21 The fact that volunteers receiving the 0 ng/kg dosing regimen experienced no symptoms and had no rise in serum markers of inflammation suggests there was no contamination in either the dosing equipment or the assays. The intermediate changes seen in the 0.25 and 0.75 ng/kg dosing regimens support this conclusion. In addition, our study design was further strengthened by the fact that both volunteers and investigators were blinded to study group until all the measurements and assays had been completed. Median (and interquartile range) for changes in the variable of interest in each of the low-dose regimens. CRP, C-reactive protein; TNF-α, tumour necrosis factor alpha; IL-6, interleukin 6 and IL-10, interleukin 10. Although we have been able to show that several different dose regimens cause variability, there are several limitations of our study. Our study was not designed to demonstrate differences between the dosing regimens or to demonstrate that one is superior to, or more appropriate than, the others. However a bolus of 0.25 ng/kg appears to be a reasonable choice as temperature, white cell count, CRP and TNF-α appear to vary more in this group than in others.
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Prior to the study, we speculated that there may be differences in the systemic inflammatory response between infusions and bolus dosing regimens. An infusion over 30 min may allow more time for potential endotoxinneutralizing factors to act and may also mimic the in vivo scenario where it is believed endotoxin is released over periods longer than a minute, for example, during episodes of gastrointestinal ischaemia or sepsis. However, we could not detect any dramatic differences between infusion and bolus regimens, but our study was not powered to show this.
Our study was not intended to detect relationships between changes in inflammatory markers, so it should not be surprising that there are no strong correlations between them. It does, however, serve to highlight the uncertainty in choosing the best or most clinically meaningful inflammatory marker. The clinical relevance of our results is, of course, uncertain but this potential criticism is also true of all volunteer studies and animal models.
CONCLUSIONS
We have identified several low-dose endotoxin regimens that elicit inter-individual variability in the inflammatory response. These dosing regimens could be used in future volunteer studies to test for potential predictors (e.g. TLR-4 polymorphisms) of the response to endotoxin.
